Wolfe Research Reiterates Outperform Rating on Oracle

Analyst: Alex Zukin 1 min read Reproduced verbatim
Rating
Outperform
Unchanged
Target
$215
Unchanged
Outcome
Reached
on May 29, 2026

Wolfe Research’s latest target on Oracle is now $225 (Jun 11, 2026); the median of 23 firms is $240.

Wolfe Research and Oracle logos

What the analyst said

Wolfe Research analyst Alex Zukin reiterated an Outperform rating and $215.00 price target on Oracle (NYSE: ORCL).

“ORCL delivered a quarter that signaled an “all clear” to the fear uncertainty and doubt that was seemingly in the headlines all quarter. ORCL outperformed guidance across all metrics for the first time this fiscal year with clearer commentary on strategy and confidence in demand supporting increased FY27 revenue guidance ($90B vs. $89B prior).

RPO grew $29B Q/Q (with “very strong” cRPO growth), which would have grown more if new bring-your-own-hardware deals (BYOH) were less of the mix. ORCL communicated increasing financial flexibility and creativity with BYOH deals, leading to the ability to fill demand with a lighter balance sheet burden.

While CapEx of ~$19B (+$5B vs. our estimate) was materially ahead of expectations, this was impacted by timing, and will continue to be volatile based on scheduled builds, highlighted with reiterated FY26 CapEx guidance (~ $50B), embedding a $9B Q/Q decline that is not indicative of demand.

ORCL added 400MW capacity in 3Q (~800MW added in TTM), increasing visibility in FY27 growth, while AI gross profit margins from capacity delivered this quarter came in at 32%, in line with the 30-40% margin range communicated at A-day based on fully ramped deployment.

While positive in the quarter, it is not indicative as a starting gross margin base for broader AI business, with management reaffirming the previously stated range.

Importantly, ORCL remains confident in its financial flexibility and, despite strong demand, does not expect any incremental debt funding in calendar 2026, but noted that it has embedded estimated ATM facility utilization in guidance.”

Cite this note: Price Target, "Wolfe Research Reiterates Outperform Rating on Oracle," March 11, 2026. https://price-target.com/2026/03/11/170203/
Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

ORCL trades at $101. The 23 analysts who set a target in the last 3 months range from $155 to $400, with a median of $240. This $215 target is 10% below the median.

Since the note ORCL has moved −32% (from $149). 12-month window: day 254 of 365, closes on March 11, 2027.

Track record

This call✓ Target reached on May 29, 2026, 3 months after the note.

Firm track recordWolfe Research: 91% of its 11 targets at least a year old were reached within 12 months. Accuracy ranking →

Earnings reactionOne of 16 notes after Oracle’s Mar 10 results: 4 raised · 2 cut · 8 kept. See every call →

Wolfe Research on Oracle

Wolfe Research price targets on Oracle

2 calls from March 11, 2026 to June 11, 2026. The target went from $215 to $225 (+5%). The rating stayed Buy.

Wolfe Research targetORCL share price
  1. June 11, 2026Target raised from $215 (+5%)Buy$225
  2. March 11, 2026 This noteEarliest call shownBuy$215
Share Reddit StockTwits
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.